David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA, USA.
Curr Hematol Malig Rep. 2019 Oct;14(5):469-476. doi: 10.1007/s11899-019-00539-3.
This review summarizes the role of BCL-2 in the pathogenesis of CLL, and the clinical data evaluating safety and efficacy of venetoclax, in treatment of patients with CLL, in the context of other available targeted agents.
Venetoclax, alone or in combination with other targeted agents results in high rate of durable responses and undetectable measurable residual disease. Venetoclax maintains activity across all clinical and biologic subgroups, including those with high risk disease, including CLL with chromosome 17p deletion. TLS risk can be mitigated with risk stratification and five-week administration ramp-up schedule. Venetoclax, a novel, orally bioavailable inhibitor of BCL-2 has demonstrated substantial clinical activity in the treatment of CLL. In combination with other targeted agents it can induce high disease response rates and potentially lead to MRD-negative durable remissions.
本综述总结了 BCL-2 在 CLL 发病机制中的作用，以及评估 Venetoclax（维奈托克）在治疗 CLL 患者中的安全性和疗效的临床数据，同时也考虑了其他可用的靶向药物。
Venetoclax（维奈托克）单独或与其他靶向药物联合使用可产生高持久应答率和不可检测的微小残留疾病。Venetoclax（维奈托克）在所有临床和生物学亚组中均保持活性，包括具有高风险疾病的患者，包括 17p 染色体缺失的 CLL。通过风险分层和五周给药方案逐步增加，可以减轻 TLS 风险。Venetoclax（维奈托克）是一种新型、口服生物可利用的 BCL-2 抑制剂，在治疗 CLL 方面具有显著的临床活性。与其他靶向药物联合使用时，它可以诱导高疾病缓解率，并可能导致 MRD 阴性的持久缓解。
